Natera (NASDAQ:NTRA) Stock: Insider Michael Burkes Brophy Sells 1,178 Shares

November 3, 2026 by InsiderTrades.com

Key Points

Natera CFO Michael Brophy sold 1,178 shares for approximately $502,370 under a pre-arranged Rule 10b5-1 trading plan, reducing his position by 2.37% while retaining 48,480 shares.
Natera reported quarterly revenue of $752.75 million, up 37.7% year over year, and an adjusted loss of $0.47 per share that beat analyst expectations.
Analysts maintain a generally positive view, with a consensus “Moderate Buy” rating and an average price target of $394.31; institutional investors own 99.90% of the stock.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CFO Michael Brophy sold 1,178 shares of Natera stock in a transaction that occurred on Wednesday, October 28th. The stock was sold at an average price of $426.46, for a total value of $502,369.88. Following the completion of the transaction, the chief financial officer owned 48,480 shares of the company's stock, valued at approximately $20,674,780.80. The trade was a 2.37% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

2 Biotech Stocks Shaping Up for Major Breakouts

Michael Burkes Brophy also recently made the following trade(s):

On Friday, October 30th, Michael Brophy sold 1,906 shares of Natera stock. The shares were sold at an average price of $425.55, for a total value of $811,098.30.
On Wednesday, October 28th, Michael Brophy sold 1,198 shares of Natera stock. The shares were sold at an average price of $426.34, for a total value of $510,755.32.
On Tuesday, October 27th, Michael Brophy sold 781 shares of Natera stock. The shares were sold at an average price of $406.00, for a total value of $317,086.00.
On Tuesday, August 4th, Michael Brophy sold 478 shares of Natera stock. The stock was sold at an average price of $274.22, for a total value of $131,077.16.

Natera Price Performance

Natera stock opened at $378.92 on Tuesday. The company has a market cap of $54.62 billion, a PE ratio of -278.62 and a beta of 1.50. The company has a fifty day moving average price of $378.00 and a two-hundred day moving average price of $267.14. Natera, Inc. has a 12 month low of $181.00 and a 12 month high of $437.41.

3 Under-the-Radar Healthcare Companies

Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.02. The firm had revenue of $752.75 million during the quarter, compared to analyst estimates of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm's revenue for the quarter was up 37.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.74) earnings per share. Equities research analysts anticipate that Natera, Inc. will post -1.14 earnings per share for the current year.

Institutional Investors Weigh In On Natera

Hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in Natera in the second quarter worth approximately $2,962,770,000. K.J. Harrison & Partners Inc bought a new position in Natera during the 2nd quarter valued at $5,117,000. Abbot Financial Management Inc. acquired a new position in shares of Natera during the 2nd quarter valued at $1,537,000. Eagle Health Investments LP acquired a new position in shares of Natera during the 2nd quarter valued at $4,302,000. Finally, BlueCrest Capital Management Ltd acquired a new position in shares of Natera during the 2nd quarter valued at $11,695,000. 99.90% of the stock is currently owned by institutional investors.

Natera News Summary

Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests

Here are the key news stories impacting Natera this week:

Neutral Sentiment: The CFO’s reported sale of 1,178 shares was executed under a pre-arranged Rule 10b5-1 trading plan, which may indicate scheduled portfolio diversification rather than a change in management’s outlook. The CFO retained 48,480 shares after the transaction. SEC insider transaction filing

Analyst Ratings Changes

A number of brokerages recently weighed in on NTRA. Royal Bank Of Canada boosted their price objective on shares of Natera from $350.00 to $460.00 and gave the company an "outperform" rating in a research report on Friday, September 25th. Piper Sandler raised their target price on shares of Natera from $249.00 to $363.50 and gave the stock an "overweight" rating in a report on Wednesday, August 12th. UBS Group raised their target price on shares of Natera from $290.00 to $435.00 and gave the stock a "buy" rating in a report on Wednesday, September 9th. BTIG Research lifted their target price on Natera from $320.00 to $430.00 and gave the company a "buy" rating in a research note on Tuesday, October 27th. Finally, Barclays upped their target price on Natera from $340.00 to $475.00 and gave the company an "overweight" rating in a report on Wednesday, October 7th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Natera has an average rating of "Moderate Buy" and a consensus price target of $394.31.

View Our Latest Stock Analysis on Natera

Natera Company Profile

(Get Free Report)

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.